"Liver Cirrhosis, Biliary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cirrhosis involves the destruction of small intra-hepatic bile ducts and bile secretion. Secondary biliary cirrhosis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes.
| Descriptor ID |
D008105
|
| MeSH Number(s) |
C06.130.120.135.250.250 C06.552.150.250 C06.552.630.400
|
| Concept/Terms |
Biliary Cirrhosis, Secondary- Biliary Cirrhosis, Secondary
- Cirrhosis, Secondary Biliary
- Liver Cirrhosis, Obstructive
- Obstructive Liver Cirrhosis
- Secondary Biliary Cirrhosis
Biliary Cirrhosis, Primary- Biliary Cirrhosis, Primary
- Biliary Cirrhosis, Primary, 1
- Cholangitis, Chronic Nonsuppurative Destructive
- Primary Biliary Cirrhosis
|
Below are MeSH descriptors whose meaning is more general than "Liver Cirrhosis, Biliary".
Below are MeSH descriptors whose meaning is more specific than "Liver Cirrhosis, Biliary".
This graph shows the total number of publications written about "Liver Cirrhosis, Biliary" by people in this website by year, and whether "Liver Cirrhosis, Biliary" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 2 | 0 | 2 |
| 2012 | 4 | 0 | 4 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 9 | 1 | 10 |
| 2016 | 4 | 0 | 4 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 3 | 0 | 3 |
| 2020 | 3 | 0 | 3 |
| 2021 | 2 | 0 | 2 |
| 2022 | 1 | 0 | 1 |
| 2023 | 3 | 0 | 3 |
| 2024 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Liver Cirrhosis, Biliary" by people in Profiles.
-
Primary biliary cholangitis. Lancet. 2024 Sep 14; 404(10457):1053-1066.
-
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. N Engl J Med. 2024 Feb 29; 390(9):783-794.
-
Immunopathogenesis of Primary Biliary Cholangitis, Primary Sclerosing Cholangitis and Autoimmune Hepatitis: Themes and Concepts. Gastroenterology. 2024 06; 166(6):995-1019.
-
Editorial: The evolving paradigms and treatments for primary biliary cholangitis-Authors' reply. Aliment Pharmacol Ther. 2024 01; 59(2):282.
-
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. N Engl J Med. 2024 Feb 29; 390(9):795-805.
-
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. Aliment Pharmacol Ther. 2024 01; 59(2):186-200.
-
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. Hepatology. 2023 08 01; 78(2):397-415.
-
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. J Hepatol. 2022 08; 77(2):353-364.
-
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. J Hepatol. 2021 09; 75(3):572-581.
-
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol. 2021 06; 74(6):1344-1354.